OYE Therapeutics is advancing a proprietary, high-concentration intravenous caffeine therapy aimed at rapidly restoring wakefulness and respiratory drive after general anesthesia and opioid-induced respiratory depression. The investigational drug is intended to be administered alongside naloxone, addressing the lingering sedation and compromised breathing that can persist after standard opioid reversal. Beyond routine surgical recovery, the therapy is being positioned for both military and civilian acute-care settings, reflecting earlier development supported by U.S. military grant funding. The company’s name—‘Open Your Eyes’—underscores its mission to rethink entrenched clinical problems. Bolstered by a $5.475 million Series A, OYE plans to initiate a Phase 1 clinical trial in the first quarter of 2026. The oversubscribed raise highlights investor confidence in the platform’s potential to transform overlooked therapeutic challenges. No commercial revenue or user metrics have been disclosed; the company remains pre-revenue as it progresses toward first-in-human studies.

Total raised

$5M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2025